Last quarter (Q0 0), Citius Oncology's total revenue was $―, a decrease of ― from the same quarter last year. In Q0, Citius Oncology's net income was $252.46K. See Citius Oncology’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Sep 24	Dec 23	Sep 23	Dec 22	Dec 21
Total Revenue	-	$ ―	$ ―	$ ―	$ 0.00	$ 0.00
Cost of Revenue	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Gross Profit	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Operating Expense	$ 522.07K	$ 20.57M	$ 1.01M	$ 12.12M	$ 138.12K	$ 10.11K
Operating Income	$ -522.07K	$ -20.57M	$ -1.01M	$ -12.12M	$ -138.12K	$ -10.11K
Net Non Operating Interest Income Expense	$ ―	$ ―	$ ―	$ ―	$ 493.02K	$ ―
Other Income Expense	$ ―	$ ―	$ ―	$ ―	$ 25.91K	$ ―
Pretax Income	$ -3.15K	$ -20.57M	$ -1.01M	$ -12.12M	$ 380.81K	$ -10.11K
Tax Provision	$ ―	$ 576.00K	$ ―	$ 576.00K	$ ―	$ ―
Earnings From Equity Interest Net Of Tax	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Net Income Common Stockholders	$ 633.27K	$ -21.15M	$ 2.42M	$ -12.70M	$ 380.81K	$ -10.11K
Basic EPS	$ 0.04	$ -0.31	$ 0.27	$ -0.19	$ ―	$ >-0.01
Diluted EPS	$ 0.04	$ -0.31	$ 0.27	$ -0.19	$ ―	$ >-0.01
Basic Average Shares	$ 4.31M	$ 68.05M	$ 6.60M	$ 67.50M	$ ―	$ 8.94M
Diluted Average Shares	$ 4.31M	$ 68.05M	$ 6.60M	$ 67.50M	$ ―	$ 8.94M
Dividend Per Share	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Operating Income As Reported	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Basic E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Diluted E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Rent Expense Supplemental	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Expenses	$ 522.07K	$ 20.57M	$ 1.01M	$ 12.12M	$ 138.12K	$ 10.11K
Net Income From Continuing And Discontinued Operation	$ 633.27K	$ -21.15M	$ 2.42M	$ -12.70M	$ 380.81K	$ -10.11K
Normalized Income	$ 694.00	$ ―	$ -800.33K	$ -8.91M	$ 365.27K	$ -10.11K
Interest Expense	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
EBIT	$ 114.35K	$ -20.57M	$ 2.42M	$ -12.12M	$ -138.12K	$ -10.11K
EBITDA	$ 114.35K	$ -20.57M	$ 2.42M	$ -12.12M	$ -138.12K	$ -10.11K

Currency in USD

Citius Oncology Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing